Physician profile
Mario Prete
NPI 1881642114
$737.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.46 | 2019 | |
| Pfizer INC. | $162.30 | 2019 | |
| Novo Nordisk INC | $113.11 | 2019 | |
| Glaxosmithkline, LLC. | $76.67 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $39.39 | 2019 | |
| Amgen INC. | $39.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.51 | 2019 | |
| Abbvie INC. | $20.97 | 2019 | |
| Sanofi Pasteur INC. | $14.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.64 | 2019 | |
| Shire North American Group INC | $11.53 | 2019 | |
| Merck Sharp & Dohme LLC | $11.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Prete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.